amisulpride 50 winthrop amisulpride 50 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride -
amisulpride winthrop amisulpride 100mg/ml oral solution bottle
sanofi-aventis australia pty ltd - amisulpride -
sulprix amisulpride 100 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 400 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian tablet 200 mg
sanofi-aventis singapore pte. ltd. - amisulpride - tablet - 200 mg - amisulpride 200 mg
solian 100 amisulpride 100 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian amisulpride 100mg/ml oral solution bottle
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; hydrochloric acid; propyl hydroxybenzoate; purified water; potassium sorbate; saccharin sodium; gluconolactone; sodium gluconate; flavour - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride thame 100mg/ml sugar free oral solution
syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - amisulpride - oral solution - amisulpride 100 mg/ml - psycholeptics
sulprix amisulpride 50 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apotex-amisulpride 100 mg tablet blister pack
gm pharma international pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; methylcellulose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.